Research News
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Page: 107
Submitted: 4 November 2023; Revised: 24 November 2023; Accepted: 27 November 2023; Published online first: 28 November 2023 A study by Meijboom et al. aimed to compare the risk of and… Read More »
Switches between biosimilars and their reference products
Submitted: 22 November 2023; Revised: 24 November 2023; Accepted: 27 November 2023; Published online first: 28 November 2023 Biologicals are the fastest-growing class of medications in the United States and account… Read More »
Biosimilar epoetin for cancer and chemotherapy-induced anaemia in the US
Page: 122
Biosimilars are biological drug products that are highly similar to reference products in analytic features, pharmacokinetics and pharmacodynamics, immunogenicity, safety and efficacy. Biosimilar epoetin received US Food and Drug Administration… Read More »
Poor traceability of biologicals in UK ADR reporting indicates the need for improvements to ensure patient safety
Submitted: 27 January 2020; Revised: 29 January 2020; Accepted: 29 January 2020; Published online first: 25 February 2020 Biological medical products (biologicals) are derived from living cells or organisms. Due to… Read More »
HIV patients will accept generic treatments
Human immunodeficiency virus (HIV) patients in high-income countries are likely to accept the introduction of generic antiretroviral (ARV) drugs, according to a study carried out by researchers in Ireland [1].… Read More »
Healthcare professionals will accept generic HIV treatments
Healthcare professionals working with HIV patients in high-income countries are likely to accept the introduction of generic antiretroviral drugs (ARVs), according to a study carried out by researchers in Ireland… Read More »